ASB8: A Potential Drug Target for Alzheimer's Disease (G140461)

Target Name: ASB8

NCBI ID: G140461

ASB8

ASB8: A Potential Drug Target for Alzheimer's Disease

ASB8 (ASB8 variant 2) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the beta-amyloid protein, which is a hallmark of Alzheimer's disease and is thought to contribute to the destruction of nerve cells in the brain that is responsible for the symptoms of the disease.

Recent studies have suggested that ASB8 may be a drug target or biomarker for the treatment of Alzheimer's disease. This is because ASB8 is known to interact with several drugs that are currently being used to treat the disease, including drugs that target the beta-amyloid protein.

One of the drugs that is known to interact with ASB8 is bevordera, a drug that is used to treat Alzheimer's disease. Bevordera works by inhibiting the activity of a protein called BACE1, which is a key enzyme that breaks down beta-amyloid protein. By inhibiting the activity of BACE1, bevordera is able to reduce the formation of beta-amyloid plaques, which are thought to contribute to the development and progression of Alzheimer's disease.

Another drug that is known to interact with ASB8 is donanemab, which is used to treat Alzheimer's disease. Donanemab works by targeting a protein called A尾42, which is a modified form of beta-amyloid protein that is thought to contribute to the development and progression of Alzheimer's disease.

In addition to these drugs, there are also several other studies that have suggested that ASB8 may be a potential drug target or biomarker for the treatment of Alzheimer's disease. For example, some researchers have suggested that ASB8 may be involved in the development of neurodegeneration, which is a condition in which the brain is damaged or destroyed. Additionally, ASB8 has been shown to interact with several other proteins that are involved in the development and progression of Alzheimer's disease, including Tau and APP.

Overall, while more research is needed to fully understand the role of ASB8 in the development and progression of Alzheimer's disease, it is clear that ASB8 is an important protein that is being studied in order to develop new and effective treatments for this debilitating disease.

Protein Name: Ankyrin Repeat And SOCS Box Containing 8

Functions: May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

The "ASB8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASB8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets